Welcome to our dedicated page for Oncotelic Therapeutics news (Ticker: OTLC), a resource for investors and traders seeking the latest updates and insights on Oncotelic Therapeutics stock.
Oncotelic Therapeutics Inc (OTLC) is a clinical-stage biopharmaceutical company advancing innovative therapies for cancer treatment through precision medicine and targeted drug development. This page consolidates official news releases and verified updates, providing stakeholders with a reliable resource for tracking the company’s progress in oncology research.
Investors and industry observers will find timely information on clinical trial milestones, regulatory developments, and strategic partnerships with pharmaceutical collaborators. The curated news feed also covers financial disclosures and operational updates critical for assessing OTLC’s position in the competitive oncology therapeutics market.
Content is organized to highlight key areas of interest including R&D advancements, technology innovations, and corporate governance updates. Regular visitors can stay informed about the company’s efforts to address unmet medical needs through its pipeline of novel cancer therapies.
Bookmark this page for direct access to Oncotelic Therapeutics’ latest announcements, or subscribe to Stock Titan’s alerts for real-time updates on OTLC’s developments in oncology research and biopharmaceutical collaborations.
Oncotelic Therapeutics (OTCQB:OTLC) announced that CEO Dr. Vuong Trieu will deliver a keynote presentation on their innovative Deciparticles™ platform at the IDDST-Europe Conference in Stockholm, June 18-20, 2025.
Deciparticles represent a breakthrough in drug delivery technology as sub-20 nm nanoparticles designed to overcome challenges in delivering insoluble drugs to solid tumors. The platform has demonstrated success in formulating over 90% of tested water-insoluble drugs, including taxanes.
Key highlights include:
- Enhanced tumor penetration and superior antitumor efficacy compared to conventional formulations
- Integration of biomarker-driven strategies using DNA methylation signatures
- Lead candidate Sapu-001 showing promising preclinical results with higher maximum-tolerated dose and reduced toxicity
The presentation is scheduled for June 19, 2025, at 10:30 CET, with Phase 1 clinical trials for Sapu-001 anticipated later in 2025.
Oncotelic Therapeutics (OTCQB:OTLC) has reported its FY 2024 financial results, marking a transformational year with significant developments. The company's joint venture, GPM Biotechnology , achieved GMP certification for its San Diego facility and obtained a Drug Manufacturing License. The facility is developing 6 nanoparticle compounds, including OT-101, with two compounds approaching IND filing stage.
The company has partnered with Shanghai Medicilon to utilize their rapid IND platform for up to 20 new filings. OT-101 is currently in Phase 3 trials for pancreatic cancer and has completed a phase 1 combination trial with IL-2. The company has also launched PDAOAI, an AI platform specifically designed for pharmaceutical regulatory processes.
Financially, OTLC reported a reduced net loss of $4.52M in FY 2024, compared to $7.90M in FY 2023. The improvement was primarily due to lower goodwill impairment ($2.9M decrease) and reduced general administrative expenses. The company recorded no service revenue in 2024, compared to $70,000 in 2023.
Oncotelic Therapeutics (OTCQB:OTLC) has published groundbreaking research on glioblastoma (GBM) treatment, revealing that high TGFB2 gene methylation correlates with improved overall survival in patients, surpassing the predictive value of MGMT and TGFB1 methylation.
The study identified several genes and pathways linked to TGFB2 methylation that improve survival outcomes, including T-cell activation, antigen processing, and Toll-like receptor pathways. The research also found that MALT1 mRNA negatively impacted survival rates, suggesting a potential target for therapy.
To facilitate research collaboration, Oncotelic has launched its proprietary PDAOAI communication platform, allowing researchers to interact with the paper and referenced articles through a single interface. This marks the company's first publication utilizing their proprietary AI technology.
Oncotelic Therapeutics (OTCQB:OTLC) has successfully completed a Phase 1 clinical trial evaluating OT-101 in combination with IL-2 for advanced or metastatic solid tumors. The trial demonstrated a tolerable safety profile with no unexpected safety signals at the planned dosing schedule.
The company presented these findings at the 5th Symposium on World Cancer Research (SWCR) 2025, where CEO Dr. Vuong Trieu discussed TGFβ2's role in immune suppression and OT-101's development progress. Key developments include:
- OT-101 is currently in a Phase 3 STOP-PC study for pancreatic cancer, combined with mFOLFIRINOX
- The company plans to advance OT-101 plus IL-2 into further clinical studies with checkpoint inhibitors
- Future trials will explore combinations in solid tumors including lung cancer, melanoma, and colorectal cancer
Oncotelic Therapeutics (OTCQB:OTLC), a leader in RNA-based therapeutics, has announced a strategic partnership with Shanghai Medicilon (688202.SH) to accelerate its drug development pipeline. Through this collaboration, Oncotelic and its subsidiary SAPU Bioscience will utilize Medicilon's rapid IND development platform to support up to 20 Investigational New Drug projects.
Currently, six INDs are already ongoing, focusing on next-generation anticancer agents. This partnership will leverage Medicilon's integrated platform for drug discovery, pharmaceutical research, and preclinical development to expedite regulatory pathways for upcoming submissions.
Dr. Vuong Trieu, Chairman and CEO of Oncotelic and SAPU, described the partnership as a "game-changer" for their development programs. Dr. Chen Chunlin, Founder and CEO of Medicilon, emphasized their organization's comprehensive services from early discovery to IND registration, designed to accelerate the translation of Oncotelic and SAPU's pipeline into new therapeutic options for patients.
Oncotelic Therapeutics (OTCQB:OTLC) has announced that CEO Vuong Trieu will deliver a featured presentation at the SWCR 2025 Conference on March 24th, focusing on Transforming Growth Factor Beta 2 (TGFB2) research. The presentation will explore TGFB2's role in cancer, lupus, and aging pathways.
The research highlights how high TGFB2 expression affects tumor-associated macrophage infiltration, disrupts antigen presentation, and creates resistance to immunotherapy. A significant portion will cover the development of OT-101, their antisense therapeutic targeting TGFB2, currently in Phase 3 clinical trials (STOP-PC study) for pancreatic ductal adenocarcinoma.
The presentation will examine how TGFB2 inhibition, either alone or combined with immune checkpoint inhibitors or interferon-based strategies, could enhance immune response and therapeutic efficacy. Dr. Trieu emphasizes TGFB2's role as a master regulator of immune suppression across multiple chronic diseases.
Oncotelic Therapeutics (OTCQB:OTLC) has announced the implementation of its AI platform PDAOAI, designed for document search and analysis in knowledge-based industries. The platform, accessible via PDAO tokens, uses advanced semantic filtering and LLM-based contextual answering to enable precise queries across large document sets.
The system has already demonstrated success at Sapu Bioscience, a subsidiary of GMP Biotechnology (where Oncotelic holds 45% ownership), helping achieve GMP compliance within one year through efficient staff training and SOP implementation. The platform will be governed through Pet2DAO using PDAO tokens, ensuring transparent, community-driven governance.
Oncotelic Therapeutics (OTCQB:OTLC) announced its upcoming presentations at SITC 2024, led by Dr. Cynthia Lee, VP of R&D. The company will present three abstracts focusing on TGFB2 therapeutics and cancer research:
1. Abstract 198: Examining TGFB2 mRNA levels' interaction with various markers in PDAC survival
2. Abstract 218: Studying prognostic impact of TGFB2 mRNA levels in low-grade gliomas
3. Abstract 1444: Meta-analysis comparing treatments for unresectable PDAC tumors
Dr. Lee, who leads the company's R&D programs and GMP facility in San Diego, will present the Sapu Bio pipeline of TGFB2 therapeutics.
Oncotelic Therapeutics (OTCQB:OTLC) has announced its fourth publication in its TGFB2 research series. Clinical data revealed significant survival improvements in pancreatic cancer patients with low expression levels of both TGFB2 and either IRF9 or IFI27, extending median overall survival from 16-20 months to 72 months. This validates the therapeutic potential of targeting IRF9 and IFI27 knockdown in TGFB2 therapeutics. The company has published four peer-reviewed articles focusing on TGFB2's role in various cancers, including pancreatic ductal adenocarcinoma, low-grade gliomas, and pediatric diffuse intrinsic pontine glioma.
Oncotelic Therapeutics (OTCQB:OTLC) announced its participation at the Precision in Drug Discovery & Preclinical Summit in San Diego. Dr. Wen-Han Chang, Nanomedicine Sr. Manager, and Dr. Tara Zand, Research Scientist, presented the company's Sapu Bio pipeline of TGFB2 therapeutics. Both scientists are focused on developing treatments for pancreatic and brain cancers through nanomedicine and precision drug development approaches.
